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Three proteins in mature myelin (Nogo, MAG, and OMgp) have been purported to be critical in causing both
regenerative failure and minimal sprouting after CNS injury. However, the role of this repulsive trio in vivo has
been controversial. Lee et al., in this issue ofNeuron, provide evidence that genetically deleting all threemajor
myelin inhibitors either singly or all together does not result in regeneration after spinal cord lesion, and the
minimal sprouting that occurs, when it does, is insufficient to restore meaningful behavior.In the English translation of S. Ramon y
Cajal’s legendary textbook ‘‘Degenera-
tion and Regeneration of the Nervous
System’’ (Ramon y Cajal, 1928), he states
that, ‘‘It is doubtful whether there exists
a negative neurotropism.’’ On the
contrary, he suggests that, in various
instances of regeneration where there
occur ‘‘repulsive’’ behaviors of axons,
these types of retrogressive changes in
axon trajectory can ‘‘be explained simply
by assuming the absence in such regions
of positive neurotropic substances.’’
While Ramon y Cajal appeared to deny
the existence of actively inhibitory mecha-
nisms that could curtail the forward prog-
ress of nerve growth, he was sufficiently
forward thinking to suggest that ‘‘.this
point requires further investigation.’’
It was not until the 1980s when Martin
Berry first hypothesized that growth-
inhibitory molecules released from de-
generating CNS myelin appeared to be
adequate to explain many of the exam-
ples of both regenerative failure and
regeneration success. Indeed, he pointed
out the intriguing observations that in the
few instances where regeneration does
occur, at least in part (i.e., severed optic
axons within the retina, cut olfactory
nerves within the bulb, lesioned hypothal-
amo-hypophyseal tract axons, and
certain injured axon pathways in the early
fetal CNS), the regenerating fibers are
nonmyelinated, or perhaps yet to be
myelinated. The second half of the
1980s saw the first glimpses into the iden-
tification of specific, putatively inhibitory,
molecules within CNS myelin. The Martin
Schwab lab published several seminal
papers reporting the repulsive growth
characteristics of sensory neurons when
they encounter CNS versus PNS tissuein vitro (see Caroni and Schwab, 1988).
This was followed by the demonstration
of the inhibitory 35 and 250 kD protein
fractions of adult myelin, and then by the
discovery of the Inhibitor of Neurites-1
and -2 (IN-1/2) antibodies that neutralized
the nonpermissive substrate properties of
CNS white matter (Caroni and Schwab,
1988). This paper in particular, appearing
in the very first issue of Neuron, ignited
an era of hope that merely cancelling out
the inhibitory effects of myelin might lead
to significant axon regeneration and
robust functional recovery after spinal
cord injury (Caroni and Schwab, 1988).
Over the following decades, the 250 kD
protein—the major antigenic target of
the IN-1 antibody—was finally identified
as a member (Nogo-A, or Rtn4-A) of the
so-called Reticulon proteins, with at least
a part of the protein exposed at the oligo-
dendrocyte surface (Oertle and Schwab,
2003). This was accompanied by the
discovery of at least two more major
myelin-associated proteins with axonal
growth inhibitory properties, MAG and
OMgp, as well as the elucidation of the
various receptors for this cadre of mole-
cules in myelin that repelled regrowing
axons (reviewed in Yiu and He, 2006).
Together, Nogo, MAG, and OMgp have
come to be characterized as ‘‘potent
inhibitors’’ and likely to act synergistically
or at least redundantly to block axon
regeneration. Indeed, many in vivo
studies after spinal cord injury, especially
those related to Nogo and its receptors
using IN-1 and other (more specific)
Nogo antibodies, Nogo receptor blocking
peptides, receptor ectodomains, or
various knockout mice, have purported
to show modest to robust regeneration
of major axon tracts through and some-Neurontimes well beyond the lesion (Li et al.,
2004; Freund et al., 2006). The claims of
significant functional recovery using these
strategies in rodents to primates have
moved ever forward and, with the help
of Novartis, humanized IN-1 antibodies
are now being administered into human
paraplegics.
In this latest issue of Neuron, 22 years
after discovery of IN-1, Jae Lee and
others from the lab of Binhai Zheng
present results that make one wonder
whether the wheels of progress toward
clinical trials may, nonetheless, have
spun too rapidly. To assess the combined
contribution of the three dominant axon
growth inhibitors in myelin, they gener-
ated a complete Nogo/MAG/OMgp triple
null mutant and investigated its axon re-
growth characteristics in comparison
with single deletion animals in vitro and
after cord injury. This is a very special
null mutant, indeed, because it remains
fully viable and morphologically normal,
at least at a gross level, even with all three
isoforms of Nogo (A, B, and C, encoded
by the same gene) as well as OMgp and
MAG missing. Western blot analyses of
total brain protein extracts confirmed the
complete absence of the three proteins
and further indicated that the expression
of their common receptors was not
altered in the triple mutants.
The results of their laborious and care-
fully executed experiments on regenera-
tion were remarkably negative. Taken
together, the in vitro assays indicated
that, for P7 cerebellar granule neurons
as well as fully adult DRGs, deleting all
three inhibitors, Nogo, MAG, and OMgp,
did not lead to significantly more neurite
outgrowth on myelin than deleting Nogo
alone. For their critical in vivo regeneration66, June 10, 2010 ª2010 Elsevier Inc. 619
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ough in their use of dorsal hemisection
as well as complete transection models
to study both the corticospinal tract
(CST) and raphe-spinal (5-HT, seroto-
nergic) tract in the single and triple
knockout mice. Meticulous CST labeling
and immunohistological studies of 5-HT
proximal to, within, and beyond the lesion
led the authors to conclude that deleting
any one inhibitor (Nogo, MAG, or OMgp)
or, most importantly, all three inhibitors
simultaneously does not promote any
significant CST or serotonergic axon
regeneration through or beyond the
lesion. While there were quite subtle
behavioral defects in the intact mutants,
the authors were cautious to assay for
potential behavioral improvements after
lesion that had been at baseline levels
prior to injury. Consistent with the lack of
enhanced axon regeneration, behavioral
analyses did not reveal any significant
improvements over controls.
What about compensatory axon
sprouting? In 1998, a paper by Z’Graggen
et al. (1998) from the Schwab lab began to
explore the possibility that the inhibitory
35/250 kD proteins in myelin were not
only involved with regeneration failure
but also in limiting sprouting from both
severed and intact axons. Unilateral CST
lesions within the pyramid were gener-
ated in adult rats that were administered
IN-1 antibodies. This was followed by
BDA tracing of cortico-fugal axons and
behavioral analyses. The results showed
minimal regeneration of only a few axons
into, but not through, the lesion and, in
addition, a rather striking effect on sprout-
ing of rostrally intact cortical projection
axons across the midline into the red
nucleus and pons contralateral to the
lesioned side. Enhanced recovery of
various CST-dependent forelimb behav-
iors, and importantly, their persistence
after more proximal relesion of the
pyramid, suggested that the purported
sprouting was, in fact, the anatomical
substratum underlying the return of func-
tion. This was also the first time that
limiting sprouting/plasticity, in addition to
frank regeneration through the lesion,
was being considered as a major role
that myelin inhibitors were playing after
CNS injury. The mechanistic relationship
between the various myelin inhibitors
and the phenomenon of axonal sprouting620 Neuron 66, June 10, 2010 ª2010 Elseviehas been the subject of investigation ever
since and is also a critical aspect of the
Lee et al. (2010) manuscript. Thus, to
ascertain whether deleting the three
myelin inhibitors enhances compensatory
sprouting, again, two major descending
pathways—the raphe-spinal and CSTs—
were studied, but this time using lateral
hemisection and pyramidotomy models
of regeneration failure. Interestingly,
MAG and OMgp single mutants, but not
Nogo mutants, exhibited a small but
significant elevated level of 5-HT immuno-
reactivity on the denervated side as
compared with wild-type mice. Again,
surprisingly, this effect was not further
enhanced in the triple mutants. On the
other hand, Nogo null mutants exhibited
enhanced CST sprouting, again at levels
lower than expected based on previous
studies. OMgp mutants did not differ
significantly from controls and, strangely,
MAG mutants even displayed reduced
CST sprouting. This suggested that MAG
has some sort of neuroprotective role, at
least for CST axons, although this selec-
tivity does not make obvious sense. None-
theless, in line with this observation, the
degree of CST sprouting in the triple
mutants was similar to that of control
mice (i.e., somewhere between Nogo and
MAG mutants), suggesting antagonistic ef-
fects of deleting Nogo and MAG together.
Nogo/OMgp double mutants remain to be
studied in the Zheng lab. Thus, the effect
of the three main myelin inhibitors on the
regulation of sprouting is surely compli-
cated and, most importantly, the modest
degree of enhancement in axon sprouting
observed in the various mutants was again
insufficient to elicit any meaningful func-
tional benefits. Therefore, the authors
conclude that the physiological signifi-
cance, if any, of the enhanced sprouting
after deleting Nogo, MAG, OMgp, or all
three still remains to be established.
The question remains: if myelin is as
potently inhibitory as the published litera-
ture suggests, how could this negative
outcome in the triple null animals have
occurred? Perhaps there were hints all
along—not just from the controversial
results using injected reagents to block
myelin inhibitory mechanisms, as well as
the conflicting results from mutant
animals (which may all be a result of
incomplete lesions or labeling artifacts;
Steward et al., 2007)—but from otherr Inc.results as well. Pettigrew and Crutcher
(1999) demonstrated that neurons could
regrow axons robustly on adult white
matter if the sections were cut tangentially
along a plain precisely parallel to the
trajectory of the tract. Also, Davies et al.
(1999) demonstrated that adult sensory
neurons could, in fact, regenerate axons
at rapid rates within not only intact but
also degenerating myelinated fiber tracts
when the neurons were microtrans-
planted to produce minimal scarring
around the implant site. However, the re-
generating axons abruptly halted their
regrowth and became dystrophic when
approaching the vicinity of proteoglycan-
rich scar tissue, just as they do after any
CNS lesion. Simply modifying the proteo-
glycan matrix has consistently led to
some functional regeneration, sprouting,
or both, but again, the results of proteo-
glycan modification alone, without the
use of additional strategies, have not
been fantastic (Garcı´a-Alı´as et al., 2009).
Many studies have pointed and continue
to point to both the lack of intrinsic growth
potential in adult neurons (Park et al.,
2008) and various inhibitory cell types
and factors, in addition to proteoglycans,
within the vicinity of the glial scar as
further determinants of regeneration
failure (Busch et al., 2010). There are quite
encouraging results showing that lengthy
regeneration with incomplete functional
recovery can be obtained when PNS
bridging (supplying guidance, condi-
tioning via trophic/tropic support, and
remyelination) is combined with chondroi-
tinase (allowing some regenerating axons
in the bridge to exit and penetrate
completely through the forming scars at
the graft/host interfaces) (Houle et al.,
2006). Obviously, there are potent barriers
to CNS regeneration that remain,
although it would appear from Lee et al.
(2010) that myelin inhibitors may not be
among them. But the story does not end
here and neither does the controversy.
A paper has just appeared from the lab
of Stephen Strittmatter (Cafferty et al.,
2010) in which comparisons of regenera-
tion efficacy following hemilesions of the
thoracic spinal cord were made in mutant
mice singly, doubly, or triply lacking these
same three myelin inhibitory proteins. The
authors report striking axonal sprouting
as well as regeneration of both 5-HT and
CST axons through and well caudal to
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especially in the triple knockout mice. In
addition, they report dramatically im-
proved behavioral recovery in the triple
null mice. The divergent results between
the two studies seem, at face value, diffi-
cult to reconcile. I can only offer the
suggestion that the differences may be
due to the extent of damage created in
the various injury models that were used.
While the Lee et al. study used pyramidot-
omy, double cut dorsal hemisection, and
complete transection for their injury
models, Cafferty et al. used a single dorsal
hemisection model. This may result in the
sparing of a small portion of the lateral-
most fibers of the CST, as well as those
of the serotonergic system residing in
the dorsal cord. In turn, enhanced, func-
tionally effective local sprouting of this re-
maining contingent of axons may occur at
and beyond the lesion epicenter in the
absence of myelin inhibitors. One would
also like to know if the purportedly regen-
erating axons within the distal tract lack
myelin, at least at early stages. If they
do, then this would be strong evidence
in favor of regeneration.
At the very heart of this and other
controversies in the broader field of
regeneration biology lie two very inter-
esting phenomena that can occur when
one attempts to damage axons even with
sufficient force to cut them. First, axons
are far more resilient than one might
expect from such a thin cellular extension.
Indeed, it has been shown that axon
tracts can be stretch grown at rates of
8 mm/d and reach lengths of a remarkable10 cm without disconnection, far ex-
ceeding what one might have thought
possible (Pfister et al., 2004). Also, initially
uncut but stretched axons, which tend to
reside at the outermost edges of certain
types of lesion-making devices, in turn
become compromised and are likely to
be at increased risk of secondary axot-
omy and dieback due to not only intrinsic
mechanisms but also to inflammatory
extravasations throughout the lesion. Any
number of even minimally therapeutic
interventions can help tip the balance and
save these fibers (Busch et al., 2010).
Thus, their persistence in the treated or
genetically altered animal, but not in the
controls, may cause them to appear as
regenerating fibers because they seem to
have grown in an abnormal, meandering
course around the lesion. But this is in
fact an erroneous perception, because
they were never cut in the first place.
These types of anatomical subtleties can
make it challenging to interpret the results
from different lesion models. How these
issues factor into the interpretation of the
two studies presented here will likely be
resolved over time. For now, definitive re-
solution of what roles Nogo and the other
myelin inhibitors play after CNS injury
remains ‘‘To be continued.’’REFERENCES
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